Does the media refer more to NTLA or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Beam Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Beam Therapeutics' score of 0.81 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRSP or NTLA?

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Intellia Therapeutics. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat CRISPR Therapeutics' score of 0.72 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EDIT or NTLA?

In the previous week, Editas Medicine had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Editas Medicine's score of 0.87 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IBRX or NTLA?

In the previous week, ImmunityBio had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat ImmunityBio's score of 0.45 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QGEN or NTLA?

In the previous week, Qiagen had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Qiagen and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Qiagen's score of -0.43 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Intellia Therapeutics (NTLA) Competitors

$14.87 +1.85 (+14.19%)

As of 12:04 PM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, IBRX, and QGEN

Should you buy Intellia Therapeutics stock or one of its competitors? MarketBeat compares Intellia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), ImmunityBio (IBRX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Intellia Therapeutics currently has a consensus target price of $20.25, suggesting a potential upside of 34.85%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 41.92%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	31.01	-$412.69M	-$3.54	N/A
Beam Therapeutics	$139.74M	24.30	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Beam Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Beam Therapeutics' score of 0.81 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,592.52	-$581.60M	-$6.22	N/A
Intellia Therapeutics	$67.67M	31.01	-$412.69M	-$3.54	N/A

CRISPR Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Intellia Therapeutics. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat CRISPR Therapeutics' score of 0.72 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Intellia Therapeutics has a net margin of -597.04% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

CRISPR Therapeutics currently has a consensus price target of $65.47, indicating a potential upside of 12.97%. Intellia Therapeutics has a consensus price target of $20.25, indicating a potential upside of 34.85%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Intellia Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Editas Medicine currently has a consensus price target of $5.40, indicating a potential upside of 75.61%. Intellia Therapeutics has a consensus price target of $20.25, indicating a potential upside of 34.85%. Given Editas Medicine's stronger consensus rating and higher possible upside, equities analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Editas Medicine had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Editas Medicine's score of 0.87 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.43	-$160.06M	-$1.23	N/A
Intellia Therapeutics	$67.67M	31.01	-$412.69M	-$3.54	N/A

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Summary

Editas Medicine and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 92.02%. Intellia Therapeutics has a consensus target price of $20.25, suggesting a potential upside of 34.85%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities analysts plainly believe ImmunityBio is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, ImmunityBio had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat ImmunityBio's score of 0.45 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a net margin of -597.04% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

ImmunityBio has higher revenue and earnings than Intellia Therapeutics. ImmunityBio is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	68.37	-$351.40M	-$0.85	N/A
Intellia Therapeutics	$67.67M	31.01	-$412.69M	-$3.54	N/A

Summary

ImmunityBio beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Qiagen?

Qiagen (NYSE:QGEN) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Qiagen had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Qiagen and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Qiagen's score of -0.43 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.73	$424.88M	$1.91	19.81
Intellia Therapeutics	$67.67M	31.01	-$412.69M	-$3.54	N/A

Qiagen has a net margin of 19.16% compared to Intellia Therapeutics' net margin of -597.04%. Qiagen's return on equity of 14.40% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Qiagen has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Qiagen presently has a consensus price target of $44.98, suggesting a potential upside of 18.85%. Intellia Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 34.85%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Qiagen beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.10B	$3.36B	$6.44B	$12.38B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-4.24	18.85	23.92	24.33
Price / Sales	31.01	323.51	525.35	120.06
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	2.59	6.82	9.98	6.79
Net Income	-$412.69M	$24.20M	$3.56B	$336.91M
7 Day Performance	9.77%	-2.04%	-0.71%	0.20%
1 Month Performance	N/A	N/A	N/A	-1.56%
1 Year Performance	95.79%	49.29%	29.11%	33.79%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	3.0114 of 5 stars	$15.02 +15.3%	$20.25 +34.8%	+69.3%	$2.10B	$67.67M	N/A	600	Positive News
BEAM Beam Therapeutics	2.15 of 5 stars	$31.14 -5.4%	$46.83 +50.4%	+75.1%	$3.20B	$139.74M	N/A	510	Gap Down
CRSP CRISPR Therapeutics	2.588 of 5 stars	$54.19 -3.5%	$65.47 +20.8%	+36.9%	$5.23B	$3.51M	N/A	460	Insider Trade Options Volume
EDIT Editas Medicine	3.1914 of 5 stars	$3.34 -3.5%	$5.40 +61.7%	+52.7%	$327.02M	$40.52M	N/A	230	Gap Down
IBRX ImmunityBio	2.4712 of 5 stars	$7.24 -3.7%	$14.20 +96.1%	+164.9%	$7.58B	$113.29M	N/A	590	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, IBRX, and QGEN

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to ImmunityBio?

Summary

How does Intellia Therapeutics compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, IBRX, and QGEN

How does Intellia Therapeutics compare to Beam Therapeutics?

Do analysts rate NTLA or BEAM?

Which has stronger valuation & earnings, NTLA or BEAM?

Does the media refer more to NTLA or BEAM?

Is NTLA or BEAM more profitable?

Which has more volatility and risk, NTLA or BEAM?

Do institutionals and insiders have more ownership in NTLA or BEAM?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Which has stronger valuation & earnings, CRSP or NTLA?

Which has more risk & volatility, CRSP or NTLA?

Does the media prefer CRSP or NTLA?

Do institutionals & insiders believe in CRSP or NTLA?

Is CRSP or NTLA more profitable?

Do analysts rate CRSP or NTLA?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Which has more risk & volatility, EDIT or NTLA?

Do analysts prefer EDIT or NTLA?

Do institutionals and insiders believe in EDIT or NTLA?

Does the media prefer EDIT or NTLA?

Which has stronger earnings & valuation, EDIT or NTLA?

Is EDIT or NTLA more profitable?

Summary

How does Intellia Therapeutics compare to ImmunityBio?

Do analysts recommend IBRX or NTLA?

Do insiders & institutionals have more ownership in IBRX or NTLA?

Does the media refer more to IBRX or NTLA?

Is IBRX or NTLA more profitable?

Which has more risk & volatility, IBRX or NTLA?

Which has better valuation & earnings, IBRX or NTLA?

Summary

How does Intellia Therapeutics compare to Qiagen?

Does the media prefer QGEN or NTLA?

Which has higher earnings and valuation, QGEN or NTLA?

Is QGEN or NTLA more profitable?

Do institutionals and insiders have more ownership in QGEN or NTLA?

Which has more risk and volatility, QGEN or NTLA?

Do analysts recommend QGEN or NTLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools